

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<p>(51) International Patent Classification ⁶ : A61K 38/00</p>	<p>A2</p>	<p>(11) International Publication Number: WO 99/59609 (43) International Publication Date: 25 November 1999 (25.11.99)</p>
<p>(21) International Application Number: PCT/EP99/03431 (22) International Filing Date: 19 May 1999 (19.05.99) (30) Priority Data: MI98A001094 19 May 1998 (19.05.98) IT (71) Applicant (for all designated States except US): VANDER WAY LIMITED [IE/IE]; 17 Dame Street, Dublin 2 (IE). (72) Inventor; and (75) Inventor/Applicant (for US only): BARTORELLI, Alberto [IT/IT]; Via G. D'Arezzo, 6, I-20145 Milano (IT). (74) Agent: MINOJA, Fabrizio; Bianchetti Bracco Minoja S.r.l., Via Rossini, 8, I-20122 Milano (IT).</p>		<p>(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).</p> <p>Published <i>Without international search report and to be republished upon receipt of that report.</i></p>
<p>(54) Title: USE OF HMG PROTEINS FOR THE PREPARATION OF MEDICAMENTS HAVING CYTOTOXIC ACTIVITY</p> <p>(57) Abstract</p> <p>Pharmaceutical compositions containing as the active ingredient a protein of the HMG group, a fragment thereof or a peptide with amino acid sequence corresponding to or derived from the HMG sequence are described.</p>		

39

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

USE OF HMG PROTEINS FOR THE PREPARATION OF
MEDICAMENTS HAVING CYTOTOXIC ACTIVITY

The present invention refers to the use of HMG proteins for the preparation of medicaments having cytotoxic activity.

The invention further concerns peptides having amino acid sequence corresponding or homologous to the amino terminus region of HMG proteins.

5 The HMG proteins, also known as High Mobility Group proteins, belong to a family of highly conserved nucleoproteins associated to chromatin and involved in the regulation processes of gene expression.

Therapeutic uses of HMG proteins, (hereinafter HMG) have never been described. The most studied HMG proteins include the HMG-I and HMG-1
10 proteins.

A number of different Authors have recently reported more and more complex roles for HMG: for instance, Jayarama et al., Genes Dev.1998, 12(4):462-472 disclosed the role of HMG-I as activator of the p53 protein.

Zappavigna et al., The Embo J, 15(18), 16/9/1996, make the hypothesis
15 that the HMG-I proteins are co-factors in the transcriptional activation mediated by products coded by the family of HOX genes.

Falciala et al., J. Cell. Biol. 1997, 137(1), 19-26 report that HMG-I is not associated in a stable way with somatic cells chromosomes, differently from Histone H1.

20 Passalacqua et al., FEBS. Lett. 1997, 400(3),275-9 show that erythroleucemic murine cells accumulate HMG-I on the outer cell surface.

It has now been found that the HMG proteins or peptides derived from the sequences thereof induce in the serum of animals and humans a cytotoxic antibody response against tumor cells.

25 Said antibody response, mainly mediated by type G and M

immunoglobulins (IgG and IgM), involves significant therapeutic effects on neoplastic diseases, particularly in the treatment of carcinomas and adenocarcinomas.

5 It has also been found that the domain of HMG which is mainly responsible for the induction of the cytotoxic antibody response is situated at the N-terminus of the HMG proteins.

The invention provides therefore pharmaceutical compositions containing as the active ingredient a protein of the HMG group, a fragment thereof or a peptide with amino acid sequence corresponding to or derived
10 from the HMG sequence.

Preferred HMG proteins include mammalian HMG-I and HMG-1 proteins.

Preferably, the fragment comprises the N-terminus sequence and the peptide has sequence corresponding or derived from the N-terminus sequence of HMG.

15 The term "HMG-I protein" or " HMG-1 proteins" refers to any non-histone chromosomal protein with an homology of at least 70%, preferably higher than 80%, and even more preferably higher than 90%, with the sequences of human HMG-I reported in the SWISS-PROT data-base under accession number P17096 or with the sequences of human HMG-1 reported
20 in the SWISS-PROT data-base under accession number P09429 respectively.

The invention also refers to HMG mutants obtained by addition, deletions or conservative substitutions of amino acids . Said mutants may be obtained, for example, by site-directed mutagenesis methods.

25 The HMG which may be used according to the invention may be of different origin, preferably of mammalian origin, for instance of man, goat, mouse, pig, rabbit, rat.

The term" peptide having amino acid sequence corresponding to or derived from the sequence of HMG protein" refers to a peptide having from

10 to 40 amino acids, preferably from 10 to 30 amino acids and more preferably from 10 to 25 amino acids, with sequence having homology of at least 70%, and preferably higher than 80%, with the HMG sequences as defined above.

5 The peptide 1-19 of HMG-I is commercially available from Santa Cruz Biotechnology, Santa Cruz, CA, USA.

The invention refers also to the peptides different from that above reported, and to the mono- or polyclonal antibodies recognising said peptides and HMG. Said antibodies may used in therapy or in diagnostic and
10 immunohistochemical methods.

The HMG may be prepared by conventional extractive or recombinant DNA methods. The genes coding for HMG are in fact mostly known and may be inserted into suitable expression vectors for prokaryotic or eukaryotic cells.

15 The peptides of the invention may be prepared by conventional methods of peptide synthesis, both in solid and in homogeneous phase. The peptides of the invention may also be stabilised versus the metabolic degradation, e.g. versus proteases, by means of conventional methods. These methods rely on the use of non-natural D-amino acids, retro inverted bonds or substitutions on
20 the terminal NH_2 or COOH groups or on other groups of the sequence amino acids.

The peptides of the invention may also be inserted into the sequence of known proteins, for example albumin, to give chimeric proteins having desired stability, pharmacokinetic and carrier properties.

25 The amino acid sequences may also be changed by means of conservative amino acid substitutions, such as that disclosed in H. Neurath and R.L. Hill "The Proteins", Academic Press, N. Y., USA, 1979.

Alternatively, the peptides may be obtained by means of recombinant

DNA methods. To this aim, suitable DNA sequences, obtained by synthesis or by PCR methods using suitable primers on HMG-I gene sequences, are inserted into expression vectors for prokaryotic or eukaryotic cells, according to known methods.

5 For the intended therapeutic uses, HMG, their fragments or peptides will be administered suitably formulated in pharmaceutical composition, for example as reported in "Remington's Pharmaceutical Sciences Handbook", Mack Publishing Company, New York, U.S.A..

10 The compositions of the invention will contain an effective amount of the peptides (or the derivatives thereof and the chemeric proteins), for instance from 0.1 to 100 mg of peptide, and they will be administered preferably by the parenteral route, in particular by the subcutaneous or intramuscular routes. The daily amount will obviously depend on different factors, like severity of the disease, weight, sex and age of the patient, and it
15 will be determined on the basis of the toxicological, pharmacokinetic and pharmacodynamic properties of each single peptide or derivative thereof.

Generally the peptide daily dosage will be comprised between 10 and 1500 μmol per Kg of body weight and the treatment will be maintained for a long time. Also other administration route can be used, for example the oral
20 route using liposome formulations or other techniques known for the administration of peptides or proteins by the gastroenteric route, as described in WO93/25583.

It is also possible the sublingual administration, using granules or solutions to be dosed as drops. In such a case, the doses of HMG or peptides
25 may also be remarkably lowered since it has been noticed that it is possible to obtain a marked efficacy through this administration route.

The invention is described in more detail in the following Example.

EXAMPLE

50-60 days old female rats were treated with 30 mg of dimethylbenzanthracene (DMBA) by gastric probe, divided in three administrations separated by a seven days period. The tumors may be detected after 50-80 days.

Ninety rats were randomly divided into three groups and treated once a week for three consecutive weeks with HMG-I (30 µg/rat), with the 1-19 peptide (50 µg/rat) (Santa Cruz Biotechnology, Inc.) or with saline solution (0.5 ml/rat).

At the start of treatment, the rats weighed 170-200 g; every 7 days, the size of the tumors was measured by means of a caliber and the physical condition and the weight of the rats were checked.

At the end of the test, one week after the last injection, the animals were sacrificed by decapitation after ketamine hydrochloride anesthesia. The tumors were removed and subjected to microscopic examination. The obtained results are reported in the following Table.

HMG-I and the 1-19 peptide clearly slow down the tumor growth in comparison to the control.

The statistical analysis of the obtained data show a significant difference between control and treated groups, the latter giving comparable results.

Tumor growth in rats treated with HMG-I (30 µg/rat) and peptide 1-19 (50 µg/ml).

Group	Mean area of the tumor at the following treatment day (cm ²)			
	0	7	14	21
Controls	ND	1,7±0,9	3,1±1,3	4,0±1,8
HMG-I	ND	0,7±0,2	1,1±0,7	1,2±0,7
Peptide 1-19	ND	0,9±10,8	1,4±0,9	1,5±0,8

CLAIMS

1. Pharmaceutical compositions containing as the active ingredient a protein of the HMG group, a fragment thereof or a peptide with amino acid sequence corresponding to or derived from the HMG sequences.
2. Pharmaceutical compositions according to claim 1 containing as the active ingredient mammalian HMG-I or HMG-1 proteins.
3. Pharmaceutical compositions according to claim 2, containing HMG-I or HMG-1 of human origin or from mouse, rat, rabbit or pig.
4. Pharmaceutical compositions according to claim 1, containing an N-terminal fragment of HMG-I or HMG-1.
5. Pharmaceutical compositions according to claim 1 containing a peptide having from 10 to 40 amino acids with amino acid sequence homologous for at least 70 % to the sequence of HMG group.
6. Peptides having from 10 to 40 amino acids with amino acid sequence homologous for at least 70 % with the sequence of HMG-I proteins, other than peptide 1-19 of HMG-I.
7. Use of a protein of the HMG group, a fragment thereof or a peptide with amino acid sequence corresponding to or derived from the HMG sequence for the preparation of anti-tumor medicaments.
8. Mono- or polyclonal antibodies recognising HMG or the peptides of claim 6.
9. Use of the antibodies of claim 8 for the preparation of cytotoxic and anti-tumor medicaments.



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : A61K 38/17, C07K 14/47, A61K 39/395	A3	(11) International Publication Number: WO 99/59609 (43) International Publication Date: 25 November 1999 (25.11.99)
(21) International Application Number: PCT/EP99/03431 (22) International Filing Date: 19 May 1999 (19.05.99) (30) Priority Data: MI98A001094 19 May 1998 (19.05.98) IT (71) Applicant (for all designated States except US): VANDER WAY LIMITED [IE/IE]; 17 Dame Street, Dublin 2 (IE). (72) Inventor; and (75) Inventor/Applicant (for US only): BARTORELLI, Alberto [IT/IT]; Via G. D'Arezzo, 6, I-20145 Milano (IT). (74) Agent: MINOJA, Fabrizio; Bianchetti Bracco Minoja S.r.l., Via Rossini, 8, I-20122 Milano (IT).	(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i> (88) Date of publication of the international search report: 27 January 2000 (27.01.00)	
(54) Title: USE OF HMG PROTEINS FOR THE PREPARATION OF MEDICAMENTS HAVING CYTOTOXIC ACTIVITY (57) Abstract <p>Pharmaceutical compositions containing as the active ingredient a protein of the HMG group, a fragment thereof or a peptide with amino acid sequence corresponding to or derived from the HMG sequence are described.</p>		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

PCT/EP 99/03431

IPC 6 A61K38/17 C07K14/47 A61K39/395

IPC 6 C07K A61K

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

1-5

— / —

☒ Patent family members are listed in annex.

Charles, D

INTERNATIONAL SEARCH REPORT

International Application No.

PCT/EP 99/03431

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	EP 0 727 487 A (LEUVEN K U RES & DEV) 21 August 1996 (1996-08-21) page 2, line 3 - line 14; claims 6,7 page 2, line 42 - line 44 page 2, line 50 -page 3, line 2 page 3, line 12 - line 14 page 4, line 7 - line 12 page 4, line 32 - line 37 page 10, line 36 - line 45 page 12, line 50 -page 13, line 24	1,8
X	PATENT ABSTRACTS OF JAPAN vol. 012, no. 011 (C-468), 13 January 1988 (1988-01-13) & JP 62 166897 A (TOYO SODA MFG CO LTD;OTHERS: 01), 23 July 1987 (1987-07-23) abstract	8
X	PASSALACQUA M ET AL: "Secretion and binding of HMG1 protein to the external surface of the membrane are required for murine erythroleukemia cell differentiation." FEBS LETTERS, (1997 JAN 6) 400 (3) 275-9. , XP002123136 cited in the application page 276, column 1, paragraph 1	8
A	JAYARAMAN L ET AL: "High mobility group protein-1 (HMG-1) is a unique activator of p53." GENES AND DEVELOPMENT, (1998 FEB 15) 12 (4) 462-72. , XP002123137 cited in the application the whole document	1,7

INTERNATIONAL SEARCH REPORT

information on patent family members

International Application No

PCT/EP 99/03431

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP 0791601 A	27-08-1997	JP 9227403 A	02-09-1997
		AU 1486997 A	28-08-1997
		NZ 314286 A	28-10-1998
		US 5851986 A	22-12-1998
FR 2739292 A	04-04-1997	AU 7136196 A	17-04-1997
		BR 9610719 A	13-07-1999
		CA 2231064 A	03-04-1997
		CZ 9800947 A	15-07-1998
		EP 0854930 A	29-07-1998
		WO 9712051 A	03-04-1997
		HU 9900317 A	28-05-1999
		NO 981322 A	24-03-1998
EP 0727487 A	21-08-1996	SK 40098 A	09-09-1998
		AU 4879096 A	04-09-1996
		CA 2213237 A	22-08-1996
		CZ 9702475 A	15-07-1998
		WO 9625493 A	22-08-1996
		EP 0811061 A	10-12-1997
		FI 973354 A	16-10-1997
		HU 9800028 A	28-04-1998
		JP 11500614 T	19-01-1999
		NO 973685 A	17-10-1997
JP 62166897 A	23-07-1987	PL 321831 A	22-12-1997
		NONE	